Business
Cardiff Oncology to Present at Upcoming Investor Conferences in September
SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a
About this update from Cardiff Oncology, Inc.
[{"type":"text","content":"SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that company management will present at the Baird Global Healthcare Conference on September 12, 2023 and the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023.\n\n \n \n \n \n \n \n\n \nDetails of the presentations can be found below.\nBaird Global Healthcare Conference [only available to live participants]Location: InterContinental New York BarclayPresenter: Mark Erlander, CEOFormat: Fireside ChatDate: 09/12/2023Time: 9:05 AM ET\nH.C. Wainwright 25th Annual Global Investment ConferenceLocation: Lotte New York Palace HotelPresenter: Mark Erlander, CEOFormat: Company PresentationDate: 09/13/2023Time: 11:30 AM ET\nInterested parties can register for and access the live webcast for H.C. Wainwright by visiting the \"Events\" section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.\nAbout Cardiff Oncology, Inc.\nCardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.\nCardiff Oncology Contact:James LevineChief Financial [email protected]\nInvestor Contact:Kiki Patel, PharmD Gilmartin [email protected]\nMedia Contact:Richa KumariTaft Communications551 344-5592 [email protected]\n \n\n\n\n View original content to download multimedia:https:...